Who Paid My Doc
Amir Lotfi
Interventional Cardiology Springfield, MA Medical Doctor
NPI 1790714400 CMS profile 262262
3300 Main St, Springfield, MA 01107
General payments
$19,744
Research payments
$50,750
Ownership & investment interest
$0
Research they led as principal investigator
$779,466
Through program year 2025, Amir Lotfi of Springfield, MA is reported in the CMS Open Payments database as having received $19,744 across 122 general payments and $50,750 in research payments paid to them. Separately, studies naming them as principal investigator received $779,466 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,637 | 30 | |
| 2024 | General | $6,453 | 43 | |
| 2023 | General | $956 | 11 | |
| 2022 | General | $1,069 | 15 | |
| 2022 | Research | $27,430 | 5 | |
| 2021 | General | $2,115 | 16 | |
| 2020 | General | $212 | 3 | |
| 2020 | Research | $3,575 | 1 | |
| 2019 | General | $303 | 4 | |
| 2019 | Research | $19,745 | 1 |
Beside peers
- Amir Lotfi
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Amir Lotfi were reported at $8,637. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Amir Lotfi | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $303 | $1,097 | $329–$3,048 | $163 |
| 2020 | $212 | $473 | $161–$1,480 | $114 |
| 2021 | $2,115 | $677 | $233–$1,827 | $132 |
| 2022 | $1,069 | $978 | $333–$2,724 | $149 |
| 2023 | $956 | $1,136 | $382–$2,986 | $160 |
| 2024 | $6,453 | $1,181 | $395–$3,326 | $164 |
| 2025 | $8,637 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
1,456
Drug cost
$193,432
Branded share of claims
29.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 109 | $109,794 | |
| Xarelto Rivaroxaban | Brand | 32 | $25,642 | |
| Entresto Sacubitril/Valsartan | Brand | 14 | $13,303 | |
| Repatha Sureclick Evolocumab | Brand | 19 | $10,470 | |
| Jardiance Empagliflozin | Brand | 14 | $9,424 | |
| Brilinta Ticagrelor | Brand | 11 | $5,727 | |
| Metoprolol Succinate | Generic | 205 | $4,074 | |
| Atorvastatin Calcium | Generic | 237 | $3,272 | |
| Rosuvastatin Calcium | Generic | 39 | $1,982 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 134 | $1,942 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 40 billing codesPaid by Medicare
$97,358
Medicare patients
685
Services billed
1,094
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 65% | |
| Arthritis | 50% | |
| Heart failure | 41% | |
| Atrial fibrillation | 41% | |
| Diabetes | 39% | |
| Chronic kidney disease | 38% | |
| COPD | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
129 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Massachusetts
Eric Secemsky
Interventional Cardiology · Boston, MA
Darshan Doshi
Interventional Cardiology · Boston, MA
Charles Gibson
Interventional Cardiology · Boston, MA
Duane Pinto
Interventional Cardiology · Boston, MA
Robert Yeh
Interventional Cardiology · Boston, MA
Thomas Piemonte
Interventional Cardiology · Burlington, MA
Related records
Interventional Cardiology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.